Limei Ai
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Multiple Myeloma Research and Treatments
Papers in
-
- CRISPR and Genetic Engineering 3
- Viral Infectious Diseases and Gene Expression in Insects 2
- Histone Deacetylase Inhibitors Research 2
- Microbial Metabolic Engineering and Bioproduction 2
-
- Lymphoma Diagnosis and Treatment 2
- Co-authors
- Shanshan Yu (3 shared papers)Yang Yu (1 shared paper)Wei Sun (1 shared paper)Wei Wei (1 shared paper)Ning Zhang (2 shared papers)Shanshan Yu (1 shared paper)Yuanyuan Sun (1 shared paper)Jing Pan (1 shared paper)
- Journals
- Tumor Biology (2 papers)Scientific Reports (1 paper)BMC Microbiology (1 paper)iScience (1 paper)ESMO Open (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Limei Ai
24 papers receiving 311 citations
Peers
Comparison fields: 5 of 66
- Cancer Research 69
- Hematology 46
- Pharmacology 30
- Genetics 27
- Molecular Biology 180
Countries citing papers authored by Limei Ai
This map shows the geographic impact of Limei Ai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Limei Ai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Limei Ai more than expected).
Fields of papers citing papers by Limei Ai
This network shows the impact of papers produced by Limei Ai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Limei Ai. The network helps show where Limei Ai may publish in the future.
Co-authors
The 25 scholars most cited alongside Limei Ai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 69 | |
| 2 | 2017 | 55 | |
| 3 | 2013 | 53 | |
| 4 | 2020 | 25 | |
| 5 | 2017 | 25 | |
| 6 | 2015 | 14 | |
| 7 | 2025 | 13 | |
| 8 | 2018 | 10 | |
| 9 | 2013 | 8 | |
| 10 | 2019 | 7 | |
| 11 | 2024 | 7 | |
| 12 | 2015 | 6 | |
| 13 | 2019 | 5 | |
| 14 | 2022 | 4 | |
| 15 | 2022 | 3 | |
| 16 | 2024 | 2 | |
| 17 | [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center]. | 2015 | 2 |
| 18 | 2019 | 2 | |
| 19 | 2023 | 1 | |
| 20 | [Inhibition of TLR4 represses proliferation and invasion ability of Raji lymphoma cells]. | 2018 | 1 |
About Limei Ai
Limei Ai is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Hematology, Cancer Research and Pharmacology, having authored 25 papers that have together received 316 indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (3 papers), Ferroptosis and cancer prognosis (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), CAR-T cell therapy research (2 papers), Viral Infectious Diseases and Gene Expression in Insects (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Microbial Metabolic Engineering and Bioproduction (2 papers). The work is most often cited by research in Cancer Research (69 citations), Hematology (46 citations), Pharmacology (30 citations), Genetics (27 citations) and Molecular Biology (180 citations). Limei Ai has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Shanshan Yu, Yang Yu, Wei Sun, Wei Wei, Ning Zhang, Shanshan Yu, Yuanyuan Sun, Jing Pan, Jing Pan and Wei Wei. Their work appears in journals such as Tumor Biology, Scientific Reports, BMC Microbiology, iScience and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.